Investigational drugs in early stage clinical trials for thyrotoxicosis with hyperthyroidism

References

• Ross DS, Burch HB, Cooper DS, et al. American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343–1421.
   PubMed Web of Science ®Google Scholar
• De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388:906–918.
   PubMed Web of Science ®Google Scholar
• Gómez JM, Virgili N, Montaña E, et al. Thyroid dysfunction induced by amiodarone in Catalonia. Prevalence and characteristics. Rev Clin Esp. 1991;188:127–130.
   PubMed Web of Science ®Google Scholar
• Gómez-Sáez JM. Sunitinib for the treatment of thyroid cancer. Expert Opin Investig Drugs. 2016;25:1345–1352.
   PubMed Web of Science ®Google Scholar
• Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind phase II trial. Lancet Oncol. 2012;13:897–905.
   PubMed Web of Science ®Google Scholar
• Lazar MA. Thyroid hormone action: a binding contract. J Clin Invest. 2003;112:497–499.
   PubMed Web of Science ®Google Scholar
• Nicrodhanond AA, Ortiga-Carbalho TM, Shibusawa N, et al. Dominant role of thyrotropin-releasing hormone in the hypothalamic-pituitary-thyroid axis. J Biol Chem. 2006;281:5000–5007.
   PubMed Web of Science ®Google Scholar
• Burch HB, Cooper DS. Management of Graves´ disease. A review. JAMA. 2015;314:2544–2554.
   PubMed Web of Science ®Google Scholar
• Biondi B, Bartalena L, Cooper DS, et al. The 2015 European thyroid association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J. 2015;4:149–163.
   PubMed Web of Science ®Google Scholar
• Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352:905–917.
   PubMed Web of Science ®Google Scholar
• Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33:920–980.
   PubMed Web of Science ®Google Scholar
• Gómez N, Gómez JM, Ortí A, et al. Transient hypothyroidism after 131I therapy for Graves’ disease. Long term follow-up and predictive factors. J Nucl Med. 1995;36:1539–1542.
   PubMed Web of Science ®Google Scholar
• Cartagena L. The dilemma of how to manage Graves’ hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab. 2011;96:592–599.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European thyroid association/European group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016;5:9–26.
   PubMed Web of Science ®Google Scholar
• Moreno P, Gómez JM, Gómez N, et al. Subtotal thyroidectomy: a reliable method to achieve euthyroidism in Graves’ disease. Prognostic factors. Word J Surg. 2006;20:1950–1956.
   Google Scholar
• Conaglen HM, Tamatea JAU, Conaglen JV, et al. Treatment choice, satisfaction and quality of life in patients with Graves’ disease. Clin Endocrinol (Oxf). 2018;88:977–984.
   PubMed Web of Science ®Google Scholar
• Galofré JG, Ana M, Chacón AM, et al. Targeting thyroid diseases with TSH receptor analogs. Endocrinol Nutr. 2013;60:590–598.
   PubMed Web of Science ®Google Scholar
• Batcher EL, Tang XC, Singh BN, et al. Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am J Med. 2007;120:880–885.
   PubMed Web of Science ®Google Scholar
• Perez Diaz N, Zloh M, Patel P, et al. In silico modelling of prostacyclin and other lipid mediators to nuclear receptors reveal novel thyroid hormone receptor antagonist properties. Prostaglandins Other Lipid Mediat. 2016;122:18–22.
   PubMed Web of Science ®Google Scholar
• Mackenzie LS. Thyroid hormone receptor antagonists: from environmental pollution to novel small molecules. Vitam Horm. 2018;106:147–162.
   PubMed Web of Science ®Google Scholar
• Hwang JY, Attia RR, Zhu F, et al. Synthesis and evaluation of sulfonylnitrophenylthiazoles (SNPTs) as thyroid hormone receptor coactivator interaction inhibitors. J Med Chem. 2012;55:2301–2310.
   PubMed Web of Science ®Google Scholar
• Singh L, Pressly B, Mengeling BJ, et al. Chasing the elusive benzofuran impurity of the THR antagonist NH-3: synthesis, isotope labelling, and biological activity. J Organ Chem. 2016;81:1870–1876.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li Y, Gupta AA, et al. Identification and molecular interaction studies of thyroid hormone receptor disruptors among household dust contaminants. Chem Res Toxically. 2016;29:1345–1354.
   PubMed Web of Science ®Google Scholar
• Neumann S, Kleinau G, Costanzi S, et al. A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism. Endocrinology. 2008;149:5945–5950.
   PubMed Web of Science ®Google Scholar
• Neumann S, Eliseeva E, McCoy JG, et al. A new small-molecule antagonist inhibits Graves’ disease antibody activation of the TSH receptor. J Clin Endocrinol Metab. 2011;96:548–554.
   PubMed Web of Science ®Google Scholar
• Neumann S, Nir EA, Eliseeva E, et al. A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice. Endocrinology. 2014;155:310–314.
   PubMed Web of Science ®Google Scholar
• van Koppen CJ, de Gooyer ME, Karstens WJ, et al. Mechanism of action of a nanomolar potent allosteric antagonist of the thyroid-stimulating hormone receptor. Br J Pharmacol. 2012;165:2314–2324.
   PubMed Web of Science ®Google Scholar
• Evans M, Sanders J, Tagami T, et al. Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample. Clin Endocrinol (Oxf). 2010;73:404–412.
   PubMed Web of Science ®Google Scholar
• Furmaniak J, Sanders J, Young S, et al. In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70). Auto Immun Highlights. 2012;3:19–25.
   PubMedGoogle Scholar
• Turcu AF, Kumar S, Neumann S, et al. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves´ ophthalmopathy. J Clin Endocrinol Metab. 2013;98:2153–2159.
   PubMed Web of Science ®Google Scholar
• Gómez Sáez JM, Soler Ramón J, Casanova A. Yersinia enterocolitica and thyroid diseases in Spain. Lancet. 1979;1(8117):678–679.
   Web of Science ®Google Scholar
• Struja T, Guebelin L, Kutz A, et al. Does immunosuppressive therapy improve outcomes in Graves’ disease? A systematic review and meta-analysis. Thyroid. 2016;26:634–640.
   PubMed Web of Science ®Google Scholar
• Heemstra KA, Toes RE, Sepers, J, et al. Rituximab in relapsing Graves’ disease, a phase II study. Eur J Endocrinol. 2008;159:609–615.
   PubMed Web of Science ®Google Scholar
• Mao XM, Li HQ, Li Q, et al. Prevention of relapse of Graves’ disease by treatment with an intrathyroid injection of dexamethasone. J Clin Endocrinol Metab. 2009;94:4984–4991.
   PubMed Web of Science ®Google Scholar
• Hu Y, Tian W, Zhang -L-L, et al. Function of regulatory T-cells improved by dexamethasone in Graves’ disease. Eur J Endocrinol. 2012;166:641–646.
   PubMed Web of Science ®Google Scholar
• Huang H, Shi Y, Liang B, et al. Optimal iodine supplementation during antithyroid drug therapy for Graves’ disease is associated with lower recurrence rates than iodine restriction. Clin Endocrinol (Oxf). 2018;88:473–478.
   PubMed Web of Science ®Google Scholar
• Watt T, Cramon P, Bjorner JB, et al. Selenium supplementation for patients with Graves’ hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial. Trials. 2013;14:119.
   PubMed Web of Science ®Google Scholar
• Leo M, Bartalena L, Rotondo Dottore G, et al. Effects of selenium on short-term control of hyperthyroidism due to Graves’ disease treated with methimazole: results of a randomized clinical trial. J Endocrinol Invest. 2017;40:281–287.
   PubMed Web of Science ®Google Scholar
• Neumann S, Huang W, Eliseeva E, et al. A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. Endocrinology. 2010;151:3454–3459.
   PubMed Web of Science ®Google Scholar
• Schapira M, Raaka BM, Das S, et al. Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking. Proc Natl Acad Sci USA. 2003;100:7354–7359.
   PubMed Web of Science ®Google Scholar